Ruth Lopert

2.1k total citations
49 papers, 1.1k citations indexed

About

Ruth Lopert is a scholar working on Economics and Econometrics, General Health Professions and Management of Technology and Innovation. According to data from OpenAlex, Ruth Lopert has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Economics and Econometrics, 8 papers in General Health Professions and 8 papers in Management of Technology and Innovation. Recurrent topics in Ruth Lopert's work include Pharmaceutical Economics and Policy (30 papers), Health Systems, Economic Evaluations, Quality of Life (29 papers) and Intellectual Property and Patents (8 papers). Ruth Lopert is often cited by papers focused on Pharmaceutical Economics and Policy (30 papers), Health Systems, Economic Evaluations, Quality of Life (29 papers) and Intellectual Property and Patents (8 papers). Ruth Lopert collaborates with scholars based in Australia, United States and Canada. Ruth Lopert's co-authors include Deborah Gleeson, Kalipso Chalkidou, Michael Hensley, Karl Claxton, Thomas Wilkinson, Paul Revill, Elias Asfaw, John Cairns, Mark Sculpher and Yot Teerawattananon and has published in prestigious journals such as The Lancet, PEDIATRICS and Clinical Infectious Diseases.

In The Last Decade

Ruth Lopert

47 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruth Lopert Australia 18 605 255 169 122 96 49 1.1k
Kees de Joncheere Switzerland 14 787 1.3× 217 0.9× 82 0.5× 151 1.2× 52 0.5× 23 1.3k
Dalia Dawoud United Kingdom 21 294 0.5× 211 0.8× 77 0.5× 78 0.6× 60 0.6× 93 1.2k
Yingyao Chen China 22 380 0.6× 296 1.2× 81 0.5× 214 1.8× 72 0.8× 153 1.4k
John Kyriopoulos Greece 18 408 0.7× 538 2.1× 58 0.3× 105 0.9× 80 0.8× 135 1.4k
Livio Garattini Italy 25 825 1.4× 281 1.1× 56 0.3× 349 2.9× 50 0.5× 133 1.8k
Liana Woskie United States 11 467 0.8× 532 2.1× 46 0.3× 109 0.9× 80 0.8× 22 1.3k
Minna Johansson Sweden 12 216 0.4× 382 1.5× 111 0.7× 79 0.6× 95 1.0× 26 1.2k
Beth Woods United Kingdom 15 370 0.6× 187 0.7× 142 0.8× 130 1.1× 153 1.6× 59 1.5k
Kathryn A. Phillips United States 17 176 0.3× 259 1.0× 247 1.5× 73 0.6× 120 1.3× 30 975
Margaret Ewen Switzerland 16 1.2k 1.9× 173 0.7× 37 0.2× 424 3.5× 61 0.6× 36 1.7k

Countries citing papers authored by Ruth Lopert

Since Specialization
Citations

This map shows the geographic impact of Ruth Lopert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Lopert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Lopert more than expected).

Fields of papers citing papers by Ruth Lopert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Lopert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Lopert. The network helps show where Ruth Lopert may publish in the future.

Co-authorship network of co-authors of Ruth Lopert

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Lopert. A scholar is included among the top collaborators of Ruth Lopert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Lopert. Ruth Lopert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Morrow, Richard L., Barbara Mintzes, Patrick C. Souverein, et al.. (2022). Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality & Safety. 31(3). 179–190. 3 indexed citations
3.
Morrow, Richard L., Barbara Mintzes, Patrick C. Souverein, et al.. (2022). Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety. 45(6). 623–638. 1 indexed citations
4.
Bhasale, Alice L, Ameet Sarpatwari, Marie L. De Bruin, et al.. (2020). Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical Pharmacology & Therapeutics. 109(6). 1424–1442. 15 indexed citations
5.
Hollingworth, Samantha, Martha Gyansa‐Lutterodt, Justice Nonvignon, et al.. (2019). Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process. International Journal of Technology Assessment in Health Care. 36(1). 8–11. 18 indexed citations
6.
Son, Kyung‐Bok, Ruth Lopert, Deborah Gleeson, & Tae-Jin Lee. (2018). Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. Globalization and Health. 14(1). 101–101. 15 indexed citations
7.
Parkinson, Bonny, Catherine Sermet, Fiona Clement, et al.. (2015). Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review. PharmacoEconomics. 33(9). 905–924. 66 indexed citations
8.
Gleeson, Deborah, Hazel V. J. Moir, & Ruth Lopert. (2015). Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans‐Pacific Partnership Agreement. The Medical Journal of Australia. 202(6). 306–308. 17 indexed citations
9.
Lopert, Ruth & Rosalie Viney. (2014). Revolution then evolution: The advance of health economic evaluation in Australia. Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen. 108(7). 360–366. 3 indexed citations
10.
Carlin, John B., Kristine Macartney, K. J. Lee, et al.. (2013). Intussusception Risk and Disease Prevention Associated With Rotavirus Vaccines in Australia's National Immunization Program. Clinical Infectious Diseases. 57(10). 1427–1434. 139 indexed citations
11.
Lopert, Ruth, Francis Ruiz, & Kalipso Chalkidou. (2013). Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania. Health Policy. 112(3). 202–208. 25 indexed citations
12.
Lopert, Ruth, et al.. (2012). Medication adherence and Medicare expenditure among beneficiaries with heart failure.. PubMed. 18(9). 556–63. 25 indexed citations
13.
Regenstein, Marsha, et al.. (2012). Medication Information for Patients with Limited English Proficiency: Lessons from the European Union. The Journal of Law Medicine & Ethics. 40(4). 1025–1033. 8 indexed citations
14.
Stuart, Bruce, et al.. (2011). Does Medication Adherence Lower Medicare Spending among Beneficiaries with Diabetes?. Health Services Research. 46(4). 1180–1199. 33 indexed citations
15.
Chalkidou, Kalipso, Sean Tunis, Ruth Lopert, et al.. (2009). Comparative Effectiveness Research and Evidence‐Based Health Policy: Experience from Four Countries. Milbank Quarterly. 87(2). 339–367. 99 indexed citations
16.
Lopert, Ruth & Sara Rosenbaum. (2007). What is Fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the United States and Australia. The Journal of Law Medicine & Ethics. 35(4). 643–656. 10 indexed citations
17.
Roughead, Elizabeth E., Ruth Lopert, & Lloyd Sansom. (2007). Prices for Innovative Pharmaceutical Products That Provide Health Gain: A Comparison Between Australia and the United States. Value in Health. 10(6). 514–520. 22 indexed citations
18.
Lopert, Ruth, et al.. (2003). Use of pharmacoeconomics in prescribing research. Part 5: modelling - beyond clinical trials. Journal of Clinical Pharmacy and Therapeutics. 28(5). 433–439. 14 indexed citations
19.
Lopert, Ruth, et al.. (2002). Differential pricing of drugs: a role for cost-effectiveness analysis?. The Lancet. 359(9323). 2105–2107. 30 indexed citations
20.
Carter, Gregory, Andrew Dawson, & Ruth Lopert. (1996). Drug-Induced Delirium. Drug Safety. 15(4). 291–301. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kees de Joncheere Breakdown of academic impact, for papers by Dalia Dawoud Breakdown of academic impact, for papers by Yingyao Chen Breakdown of academic impact, for papers by John Kyriopoulos Breakdown of academic impact, for papers by Livio Garattini Breakdown of academic impact, for papers by Liana Woskie Breakdown of academic impact, for papers by Minna Johansson Breakdown of academic impact, for papers by Beth Woods Breakdown of academic impact, for papers by Kathryn A. Phillips Breakdown of academic impact, for papers by Margaret Ewen
Rankless by CCL
2026